

Appendix from Johansen et al., “The serotonin transporter promotes a pathological estrogen metabolic pathway in pulmonary hypertension via cytochrome P450 1B1”

(Pulm. Circ., vol. 6, no. 1, p. 82)

Supplementary figures




Figure S1. Inhibition of cytochrome P450 1B1 (CYP1B1) with 2,3',4,5'-tetramethoxystilbene (TMS) has no effects on mean systemic arterial pressures (SAPs). Female SERT⁺ mice were injected with 1.5 mg/kg TMS intraperitoneally for 2 weeks and compared with wild-type (WT; C57Bl/6J CBA) and SERT⁺ vehicle-treated mice. Mean SAPs were measured by cannulation of the carotid artery; $n = 7-10$. Data were analyzed by a 1-way analysis of variance followed by a Tukey post hoc test. SERT⁺: serotonin transporter is overexpressed.




Figure S2. Inhibition of cytochrome P450 1B1 (CYP1B1) with 2,3', 4,5'-tetramethoxystilbene (TMS) and monocrotaline (MCT) has no effects on mean systemic arterial pressures (SAPs). Female and male rats were given a single dose of MCT (60 mg/kg subcutaneously) and 14 days later were given TMS (3 mg/kg/day intraperitoneally) or vehicle (~5% ethanol in saline) for an additional 14 days. Mean SAPs were measured by cannulation of the carotid artery; $n = 5-11$. Data were analyzed by a 1-way analysis of variance followed by a Tukey post hoc test.